Gossamer Bio (NASDAQ:GOSS) Receives “Outperform” Rating from Wedbush

Wedbush reissued their outperform rating on shares of Gossamer Bio (NASDAQ:GOSS) in a research report report published on Friday morning,Benzinga reports. The brokerage currently has a $4.00 price objective on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Gossamer Bio in a report on Thursday, January 30th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $9.20.

Gossamer Bio Stock Up 11.5 %

Shares of GOSS opened at $1.45 on Friday. The stock has a 50 day moving average price of $1.13 and a 200 day moving average price of $0.97. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74. The stock has a market capitalization of $328.58 million, a price-to-earnings ratio of -4.53 and a beta of 1.86. Gossamer Bio has a one year low of $0.50 and a one year high of $1.55.

Gossamer Bio (NASDAQ:GOSS) last issued its earnings results on Tuesday, March 18th. The company reported ($0.15) EPS for the quarter, meeting analysts’ consensus estimates of ($0.15). Equities research analysts forecast that Gossamer Bio will post -0.28 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Gossamer Bio

Institutional investors have recently bought and sold shares of the company. Graham Capital Management L.P. acquired a new stake in shares of Gossamer Bio during the 4th quarter worth approximately $32,000. US Bancorp DE purchased a new stake in Gossamer Bio in the third quarter valued at $39,000. Fullcircle Wealth LLC acquired a new position in shares of Gossamer Bio in the 4th quarter valued at $43,000. GSA Capital Partners LLP purchased a new position in shares of Gossamer Bio during the 3rd quarter worth $67,000. Finally, Velan Capital Investment Management LP acquired a new stake in shares of Gossamer Bio during the 4th quarter worth about $68,000. 81.23% of the stock is owned by hedge funds and other institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.